文献速递眼底病与葡萄膜炎

局部多佐胺-噻吗洛尔辅助治疗新生血管性年龄相关性黄斑变性的随机临床试验

Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

这项随机安慰剂对照试验纳入52例抗VEGF治疗后持续渗出的新生血管性AMD眼,比较局部多佐胺-噻吗洛尔与人工泪液约3个月的效果。结果显示多佐胺-噻吗洛尔组中央亚field厚度和最大PED高度显著降低,但视力无显著改善。

核心结论

  • 在新生血管性AMD持续渗出眼中,局部多佐胺-噻吗洛尔相比安慰剂约3个月时带来解剖学改善但无视力提高。

临床怎么用

  • 对于抗VEGF治疗后持续渗出的新生血管性AMD眼,可考虑辅助局部多佐胺-噻吗洛尔以改善解剖指标,但不应期望视力获益。

局限性

  • 样本量较小(分析52例),随访仅约3个月,需更长期更大样本试验确定其作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Some eyes with neovascular age-related macular degeneration (AMD) have persistent exudation despite frequent intravitreal anti-vascular endothelial growth factor (VEGF) injections. Adjuvant therapies that further reduce edema may improve vision outcomes. OBJECTIVE: To compare the short-term effect of topical dorzolamide-timolol vs placebo in eyes with neovascular AMD that have persistent exudation following intravitreal anti-VEGF injections. DESIGN, SETTING, AND PARTICIPANTS: Randomized placebo-controlled clinical trial with enrollment from March 1, 2017, through October 30, 2018. Multicenter trial at 4 clinical sites in the United States. Sixty-three patients with neovascular AMD who had persistent exudation despite intravitreal anti-VEGF injections at 4-week, 5-week, or 6-week intervals. INTERVENTIONS: Patients were randomized to use dorzolamide-timolol or artificial tears for the study duration. They continued to receive the same anti-VEGF drug at the same interval as the 2 visits before enrollment for 3 additional study visits. MAIN OUTCOMES AND MEASURES: The primary outcome measure was change in mean central subfield thickness on optical coherence tomography from baseline to visit 3 (approximately 3 months). Secondary measures included change in mean maximum subretinal fluid height, mean maximum pigment epithelial detachment height, and mean visual acuity (VA). RESULTS: This trial included 52 patients. All 27 patients (100%) assigned to dorzolamide-timolol and 23 of 25 (92%) assigned to placebo were analyzed for the primary outcome. Mean (SD) age was 78.4 (7) years, and 34 of 50 patients (68%) were women. Mean (SD) injections were 20.5 (14) (range, 4-58) before enrollment. Mean (SD) baseline logMAR VA was 0.361 (0.26) (approximate Snellen equivalent, 20/50). Comparing the dorzolamide-timolol with placebo group from baseline to visit 3, mean (SD) change in central subfield thickness (primary outcome) was -36.6 (54) μm vs 1.7 (52.3) μm (difference, 30.8; 95% CI, 0.3-61.3; P = .04); secondary outcomes: maximum PED height was -39.1 (65) μm vs 1.1 (16) μm (difference, 39.6; 95% CI, 9.6-69.6; P = .01) and change in VA from baseline to visit 3 was -2.3 (5) vs 0.3 (1) letters (difference, 2.6 letters; 95% CI, -1.9 to 7.1 letters; P = .78). CONCLUSIONS AND RELEVANCE: These findings suggest use of dorzolamide-timolol in patients with neovascular AMD with persistent exudation resulted in anatomic but not visual acuity improvements compared with placebo at approximately 3 months. Additional clinical trials with longer follow-up and larger sample sizes presumably would be needed to determine the role, if any, of dorzolamide-timolol in neovascular AMD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03034772.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hsu J, Patel SN, Wolfe JD, et al. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32239190. doi:10.1001/jamaophthalmol.2020.0724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。